Japan is the third largest pharmaceuticals market in the world. As a result of the country's ageing population, there is a continuous increase in societal healthcare awareness. Japan has a number of internationally operating research companies that are actively looking for collaboration opportunities with new and innovative pharmaceutical companies. The healthcare and medical industries make up the majority of the biotechnology sector in Japan, and its expansion is an integral part of the Abe administration’s growth strategy. Over the last 30 years Japan’s biotechnology sector has grown rapidly and offers numerous opportunities for European exports of biopharmaceutical products and R&D cooperation

USDC International Trade Administration, Japan Commercial Guide, 2016
USDC International Trade Administration, Top Markets Report: Pharmaceuticals, 2016

Japan continues to be Asia’s number-one country in biotech and pharma patents (13,748 listing at least one Japanese inventor, according to WIPO), as well as a firm number-two in R&D ($170.082 billion in 2015, according to OECD).

GEN, Top Eight Asia Biopharma Clusters 2017

Table of Contents

  • Collaborative Opportunities
  • Regenerative Medicine
  • Gene Therapy
  • Blood Substitutes
  • Vaccines
  • Antibody Drugs
  • Biosimilars
  • Expert Report
  • Annual Report
  • Further Reading
  • Relevant Organisations and Trade Fairs
Please log in for full access